Endpoints For Kidney Transplant Drugs Getting FDA Attention
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will conduct a two-day workshop in September to hear from health care providers, academia and industry on potential clinical or surrogate endpoints and biomarkers for clinical trials of drugs for kidney transplant patients.